A new prostate cancer treatment could provide more effective treatment with fewer side effects according to a new report.
The study was the first to use an experimental treatment known as HIFU (high-intensity focused ultrasound) to treat areas of cancer which are only a few millimetres in size, a technique known as focal therapy.
Focal therapy is similar in principle to the 'lumpectomy' operation commonly used as an alternative to a full mastectomy in breast cancer.
One year after treatment none of the 41 men in the trial had incontinence, and just one in 10 suffered from poor erections - both common side effects of conventional treatment. The majority (95%) were also cancer-free after a year.
Researchers concluded that: "focal therapy of individual prostate cancer lesions, whether multifocal or unifocal, leads to a low rate of genitourinary side-effects and an encouraging rate of early absence of clinically significant prostate cancer".
Dr Hashim Ahmed, who led the study at University College London Hospitals NHS Foundation Trust and UCL, said: "Our results are very encouraging. We're optimistic that men diagnosed with prostate cancer may soon be able to undergo a day case surgical procedure, which can be safely repeated once or twice, to treat their condition with very few side-effects. That could mean a significant improvement in their quality of life.
"This study provides the proof-of-concept we need to develop a much larger trial to look at whether focal therapy is as effective as the current standard treatment in protecting the health of the men treated for prostate cancer in the medium and long term."
Prostate cancer is the most common cancer in men. In the UK, more than 37,000 men are diagnosed each year and the condition leads to approximately 10,000 deaths.
Standard therapy currently involves treating the whole prostate, either with radiotherapy or surgery to remove it completely.
Both methods cause damage to surrounding healthy tissue and can lead to side effects such as urinary incontinence requiring one or more pads a day (5-25%), erections insufficient for sexual intercourse (30-70%) and rectal problems (diarrhoea, bleeding, pain; 5-10%).
Owen Sharp, Chief Executive of The Prostate Cancer Charity told HuffPost Lifestyle: "We welcome the development of any prostate cancer treatment which limits the possibility of damaging side effects such as incontinence and impotence. These early results certainly indicate that focal HIFU has the potential to achieve this in the future.
"However, we need to remember that this treatment was given to fewer than 50 men, without follow up over a sustained period of time.
"We look forward to the results of further trials, which we hope will provide a clearer idea of whether this treatment can control cancer in the long term whilst ridding men of the fear that treating their cancer might mean losing their quality of life".
Other prostate cancer news:
- Cancer patient has prostate tumour removed by a robot
- Breakthrough prostate cancer drug 'too expensive' say experts